Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 401-410 of 639 results
PLoS ONE, 2018 • August 29, 2018
This study investigated the effects of ursolic acid (UA) on sub-lesional muscle pathology in a mouse model of spinal cord injury (SCI). The study found that UA improves anabolic IGF-1/mTOR signaling, ...
KEY FINDING: Ursolic acid treatment attenuates SCI induced decreases in activated forms of mTOR, and signaling intermediates PI3K, AKT, and S6K.
Medical Science Monitor, 2018 • October 18, 2018
The study examined the effects of lycopsamine on apoptosis and functional recovery after SCI in a rat model. The results showed that lycopsamine administration improves locomotory function in SCI rats...
KEY FINDING: Lycopsamine significantly improved locomotory function in SCI rats.
Spinal Cord Series and Cases, 2019 • January 1, 2019
This study assessed attitudes toward and knowledge of cannabis among a nationwide sample of people with SCI. Participants largely believed that cannabis use is safe, has potential therapeutic benefits...
KEY FINDING: Most participants believed cannabis is safe, has medicinal benefits, and should be legal.
Journal of Neuroinflammation, 2019 • May 8, 2019
The study investigated the use of mineral-coated microparticles (MCMs) for sustained delivery of interleukin-10 (IL-10) to treat spinal cord injury (SCI) in rats. Results showed that MCMs+IL-10 treatm...
KEY FINDING: MCMs effectively delivered IL-10 to the injury site, resulting in elevated IL-10 levels and suppressed inflammatory cytokines.
Spinal Cord Series and Cases, 2019 • March 19, 2019
The case report highlights the occurrence of gluteal hematomas in two patients with chronic spinal cord injury who were receiving prophylactic enoxaparin for venous thromboembolism (VTE). The authors ...
KEY FINDING: Two patients with chronic SCI developed gluteal hematomas while on prophylactic enoxaparin, requiring surgical intervention and delaying rehabilitation.
Spinal Cord Series and Cases, 2019 • June 26, 2019
This study explored the utilization of medicinal cannabis (MC) among individuals with spinal cord injury (SCI) to manage pain and other symptoms. The research compared current, past, and never users o...
KEY FINDING: Current and past MC users reported greater pain interference in daily life compared to never users.
Spinal Cord Series and Cases, 2019 • January 1, 2019
Osteoporosis and fragility fractures are prevalent and clinically meaningful in the SCI population. Prevention is a critical area of research. Although many osteoporosis medications demonstrate variab...
KEY FINDING: Bisphosphonate therapy after acute SCI may attenuate bone mineral density (BMD) loss in comparison to no treatment if administered acutely after injury.
PLoS ONE, 2012 • June 19, 2012
This study demonstrated that imatinib treatment following spinal cord injury in rats led to significant improvements in functional outcomes, including enhanced locomotor function, sensorimotor integra...
KEY FINDING: Imatinib significantly enhanced hindlimb locomotor function. By day 56 post-injury, 70% of imatinib-treated rats had regained the ability to make uncoordinated weight-supported steps.
International Journal of Ophthalmology, 2012 • April 18, 2012
The study aimed to evaluate the efficacy of topical Natamycin, produced in China, in treating fungal keratitis using a rabbit model. Rabbits with induced keratitis were treated with Natamycin, Natacyn...
KEY FINDING: Natamycin and Natacyn groups showed significantly better ulcer scores compared to the control group on days 10, 15, and 21.
Therapeutics and Clinical Risk Management, 2012 • October 18, 2012
The study aimed to investigate whether the Barthel Index (BI) underestimates the consequences of neurologic lesions when assessing the clinical outcome after Botulinum toxin type A (BoNT-A) injection....
KEY FINDING: The Barthel Index score increased in follow-up assessments, but the increase was small and only slightly significant in stroke subjects.